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Conclusion: Most of the modulation indexes proposed in the 
literature are related to the robustness and modulation of a 
plan. However, none of them has been conceived to 
appropriately predict the interplay effect in lung SABR. MIt 
has been found to be the only published index capable of 
detecting failing plans. MIt and PUMA have the same 
specificity since both detected all of the failing plans. 
However, PUMA has a greater accuracy and sensitivity. 
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Purpose or Objective: The objective of this HERO study was 
to assess the number of new cancer patients that will require 
at least one course of radiotherapy by 2025 compared to the 
2012 figure, by tumor site and European country. 
 
Material and Methods: European cancer incidence data by 
tumor site and country for 2012 and 2025 was extracted from 
the GLOBOCAN database. The projection of the number of 
new cases took into account demographic factors (age and 
size of the population). Population based stages at diagnosis 
were taken from four European countries. Incidence and 
stage data were introduced in the Australian Collaboration 
for Cancer Outcomes Research and Evaluation (CCORE) 
model,  thus producing an evidence-based proportion of 
incident cases with an indication for radiotherapy, the 
Optimal Utilization Proportion (OUP).  From these values, the 
number of cases that would require radiotherapy on an 
annual basis in each country was calculated. 
 
Results: Among the difference tumor sites, the highest 
expected relative increase by 2025 in treatment courses was 
prostate cancer (24%) while lymphoma (13%), head and neck 
(12%) and breast cancer (10%) were below the average. 
Cervical (1%) and testicular cancer (-6%) were the sites with 
the lowest expected increase. Based on the projected cancer 
distributions in 2025, a 16% expected increase in the number 
of radiotherapy treatment courses was estimated. This 
increase varied across European countries from less than 5% 
(Bulgaria, Latvia, Lithuania, Ukraine, Belarus, Estonia, 
Moldova) to more than 30% (Switzerland, Luxembourg, Malta, 
Iceland, Ireland, Albania, Cyprus). 
 
Conclusion: This HERO study showed that the need for 
radiotherapy in Europe is, on average, expected to increase 
with 16% over the next decade. The expected changes varied 
considerably between countries (range 0-38%). With the 
already existing disparity in radiotherapy resources in mind, 
the data provided here should act as a leverage point to raise 
awareness among European health policy makers of the need 
for investment in radiotherapy.  
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Purpose or Objective: Current clinical trials and studies are 
identifying hypofractionation as a viable treatment option 
when compared with current fractionation regimens. Our 
work estimates the reduction in the number of fractions 
prescribed and the potential effect on the overall demand for 
radiotherapy across the whole of England. With the evidence 
based estimates of demand for radiotherapy currently 
outstripping the supply capacity in England, this potential 
reduction in fraction demand needs to be calculated to assess 
the potential effects for radiotherapy service and 
infrastructure planning. 
 
Material and Methods: The Malthus Program, a tool for 
modelling radiotherapy demand, was used to calculate the 
potential effect of three hypofractionation studies/trials for 
the population of England. Well-published and potential 
clinical indications for hypofractionation have been modelled 
for prostate cancer, non-small cell lung cancer (NSCLC) and 
breast cancer. The hypofractionation indications for 
radiotherapy were mapped into the original Malthus clinical 
decision trees and simulations completed to study the effects 
of hypofractionation on demand. 
 
Results: If the CHHiP prostate trial achieves universal uptake 
throughout England then it has the potential to reduced 
radiotherapy demand by 3,500 fractions per million 
population (#pmp). SBRT for medically inoperable (or refusal 
of surgery) for stage 1 and stage 2 NSCLC has the potential to 
reduce the demand by a further 700 #pmp. The FAST-Forward 
trial, using 5# instead of 15# for T1-3 N0-1 M0 breast cancer 
